PM
RARE icon

Prosight Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Prosight Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-44,600
Closed -$2.07M – 35
2017
Q4 		$2.07M Buy
+44,600
New +$2.19M 1.52% 22

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Prosight Management's RARE Position: Q1 2018 in Review

Prosight Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2018, closing a stake of 44,600 shares — an estimated $2.07M sold.

Prosight Management first reported a position in RARE in Q4 2017 and held it in 1 quarter. The position peaked at $2.07M in Q4 2017. 165 funds tracked by Wall St. Rank hold RARE as of Q1 2018.

  • Prosight Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2018 after selling out during the quarter.
  • Prosight Management sold 44,600 Ultragenyx Pharmaceutical shares in Q1 2018, an estimated $2.07M.
  • Prosight Management first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and held it in 1 quarter.
  • Prosight Management's Ultragenyx Pharmaceutical position peaked at $2.07M in Q4 2017.
  • 165 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2018.

Based on Prosight Management's 13F filing for Q1 2018, filed 14 May 2018.